 Xeris Pharmaceuticals continues to pop up on my newsfeed and momentum scanners. Unfortunately, I threw XERS in my speculative portfolios closet and havent paid attention despite it hitting new 52-week highs. The company recently received European approval for their premixed RTU liquid glucagon auto-injector for very low blood sugar. 